CN102101886A - 构象改变的重组干扰素晶体、其三维结构及应用 - Google Patents

构象改变的重组干扰素晶体、其三维结构及应用 Download PDF

Info

Publication number
CN102101886A
CN102101886A CN2009102593392A CN200910259339A CN102101886A CN 102101886 A CN102101886 A CN 102101886A CN 2009102593392 A CN2009102593392 A CN 2009102593392A CN 200910259339 A CN200910259339 A CN 200910259339A CN 102101886 A CN102101886 A CN 102101886A
Authority
CN
China
Prior art keywords
interferon
rabbit
alpha
residue
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009102593392A
Other languages
English (en)
Chinese (zh)
Inventor
魏光文
王大成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SICHUAN HUIYANG LIFE ENGINEERING Co Ltd
Original Assignee
SICHUAN HUIYANG LIFE ENGINEERING Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SICHUAN HUIYANG LIFE ENGINEERING Co Ltd filed Critical SICHUAN HUIYANG LIFE ENGINEERING Co Ltd
Priority to CN2009102593392A priority Critical patent/CN102101886A/zh
Priority to EP10836926.5A priority patent/EP2514761B1/en
Priority to PCT/CN2010/002055 priority patent/WO2011072487A1/zh
Priority to ES10836926.5T priority patent/ES2631028T3/es
Priority to US13/516,947 priority patent/US8846025B2/en
Priority to MYPI2012002756A priority patent/MY169650A/en
Priority to JP2012543445A priority patent/JP2013514279A/ja
Priority to CA2784624A priority patent/CA2784624C/en
Priority to HK13104725.9A priority patent/HK1177749B/xx
Priority to KR1020127017945A priority patent/KR20120108985A/ko
Priority to AU2010333574A priority patent/AU2010333574B2/en
Priority to CN201080057897.1A priority patent/CN102770447B/zh
Priority to SG2012044889A priority patent/SG181785A1/en
Priority to US12/971,956 priority patent/US8415151B2/en
Publication of CN102101886A publication Critical patent/CN102101886A/zh
Priority to US14/461,360 priority patent/US9273109B2/en
Priority to JP2016058155A priority patent/JP2016128507A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Evolutionary Biology (AREA)
CN2009102593392A 2009-12-18 2009-12-18 构象改变的重组干扰素晶体、其三维结构及应用 Pending CN102101886A (zh)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CN2009102593392A CN102101886A (zh) 2009-12-18 2009-12-18 构象改变的重组干扰素晶体、其三维结构及应用
CA2784624A CA2784624C (en) 2009-12-18 2010-12-16 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
AU2010333574A AU2010333574B2 (en) 2009-12-18 2010-12-16 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
ES10836926.5T ES2631028T3 (es) 2009-12-18 2010-12-16 Cristal de interferón recombinante con configuración espacial alterada, estructura tridimensional y sus usos
US13/516,947 US8846025B2 (en) 2009-12-18 2010-12-16 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
MYPI2012002756A MY169650A (en) 2009-12-18 2010-12-16 Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
JP2012543445A JP2013514279A (ja) 2009-12-18 2010-12-16 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用
EP10836926.5A EP2514761B1 (en) 2009-12-18 2010-12-16 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
HK13104725.9A HK1177749B (en) 2009-12-18 2010-12-16 Crystalline recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
KR1020127017945A KR20120108985A (ko) 2009-12-18 2010-12-16 변경된 공간 배치, ３차원 구조를 갖는 결정형 재조합 인터페론 및 이의 용도
PCT/CN2010/002055 WO2011072487A1 (zh) 2009-12-18 2010-12-16 空间构象改变的重组干扰素的晶体、其三维结构及应用
CN201080057897.1A CN102770447B (zh) 2009-12-18 2010-12-16 空间构象改变的重组干扰素的晶体、其三维结构及应用
SG2012044889A SG181785A1 (en) 2009-12-18 2010-12-16 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
US12/971,956 US8415151B2 (en) 2009-12-18 2010-12-17 Crystalline recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
US14/461,360 US9273109B2 (en) 2009-12-18 2014-08-15 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
JP2016058155A JP2016128507A (ja) 2009-12-18 2016-03-23 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009102593392A CN102101886A (zh) 2009-12-18 2009-12-18 构象改变的重组干扰素晶体、其三维结构及应用

Publications (1)

Publication Number Publication Date
CN102101886A true CN102101886A (zh) 2011-06-22

Family

ID=44154975

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009102593392A Pending CN102101886A (zh) 2009-12-18 2009-12-18 构象改变的重组干扰素晶体、其三维结构及应用
CN201080057897.1A Active CN102770447B (zh) 2009-12-18 2010-12-16 空间构象改变的重组干扰素的晶体、其三维结构及应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080057897.1A Active CN102770447B (zh) 2009-12-18 2010-12-16 空间构象改变的重组干扰素的晶体、其三维结构及应用

Country Status (11)

Country Link
US (3) US8846025B2 (enExample)
EP (1) EP2514761B1 (enExample)
JP (2) JP2013514279A (enExample)
KR (1) KR20120108985A (enExample)
CN (2) CN102101886A (enExample)
AU (1) AU2010333574B2 (enExample)
CA (1) CA2784624C (enExample)
ES (1) ES2631028T3 (enExample)
MY (1) MY169650A (enExample)
SG (1) SG181785A1 (enExample)
WO (1) WO2011072487A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847564A (zh) * 2015-05-12 2018-03-27 远东超级实验室有限公司 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途
CN111508568A (zh) * 2020-04-20 2020-08-07 腾讯科技（深圳）有限公司 分子生成方法、装置及计算机可读存储介质和终端设备
CN113223631A (zh) * 2021-05-06 2021-08-06 吉林大学 一种晶体结构解析方法及系统

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9830422B1 (en) * 2013-07-22 2017-11-28 The Curators Of The University Of Missouri In silico biological and pharmaceutical modeling
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
WO2019134318A1 (zh) * 2018-05-09 2019-07-11 深圳晶泰科技有限公司 药物晶体结构全景分析系统及其全景分析方法
CN111658779A (zh) * 2020-06-22 2020-09-15 四川大学华西医院 治疗新型冠状病毒肺炎的联合用药物
CN119670712B (zh) * 2024-11-28 2025-10-03 中国人民解放军总医院 基于bert模型的临床知情同意书智能推荐装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311035A (zh) * 2001-02-28 2001-09-05 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
CN1710197A (zh) * 2005-06-17 2005-12-21 徐州师范大学 可变色彩色纤维防伪纸

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
WO1999045389A2 (en) 1998-03-06 1999-09-10 Abbott Lab Ligand screening and design by x-ray crystallography
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
EP2292652A2 (en) 2000-11-03 2011-03-09 Pestka Biomedical Laboratories, Inc. Interferons uses and compositions related thereto
AU2002223350A1 (en) * 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
US20060035327A1 (en) 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
FR2823764B1 (fr) * 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
CN101001644B (zh) * 2003-08-28 2011-09-21 辉阳科技美国公司 空间构象改变的干扰素及其应用
AU2004269390A1 (en) * 2003-08-28 2005-03-10 Huiyangtech (Usa), Inc. Uses of spatial configuration to modulate protein function
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
KR101431172B1 (ko) 2003-08-28 2014-08-19 수퍼랩 파 이스트 리미티드 변경된 공간 구조를 갖는 인터페론의 용도
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
CN1740197B (zh) * 2004-08-26 2010-05-12 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
JP2006083126A (ja) * 2004-09-17 2006-03-30 Institute Of Physical & Chemical Research タンパク質の結晶化試薬キット及び試薬キットを利用した結晶化スクリーニング方法
WO2006134497A2 (en) 2005-03-09 2006-12-21 Guangwen Wei Uses of recombinant super-compound interferons
JP4744979B2 (ja) * 2005-08-24 2011-08-10 独立行政法人理化学研究所 ゼオライトを用いたタンパク質結晶化方法
JP2008050225A (ja) * 2006-08-25 2008-03-06 National Institute Of Advanced Industrial & Technology たんぱく質の合理的な結晶化条件探索法
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
US20130184437A9 (en) 2011-06-08 2013-07-18 Guangwen Wei Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311035A (zh) * 2001-02-28 2001-09-05 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US20040202641A1 (en) * 2001-02-28 2004-10-14 Sichuan Biotechnology Research Center Recombinant super-compound interferon
CN1710197A (zh) * 2005-06-17 2005-12-21 徐州师范大学 可变色彩色纤维防伪纸

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847564A (zh) * 2015-05-12 2018-03-27 远东超级实验室有限公司 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途
CN107847564B (zh) * 2015-05-12 2021-11-09 远东超级实验室有限公司 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途
CN111508568A (zh) * 2020-04-20 2020-08-07 腾讯科技（深圳）有限公司 分子生成方法、装置及计算机可读存储介质和终端设备
CN111508568B (zh) * 2020-04-20 2023-08-29 腾讯科技（深圳）有限公司 分子生成方法、装置及计算机可读存储介质和终端设备
CN113223631A (zh) * 2021-05-06 2021-08-06 吉林大学 一种晶体结构解析方法及系统
CN113223631B (zh) * 2021-05-06 2024-05-24 吉林大学 一种晶体结构解析方法及系统

Also Published As

Publication number Publication date
US20120308520A1 (en) 2012-12-06
MY169650A (en) 2019-04-25
JP2016128507A (ja) 2016-07-14
JP2013514279A (ja) 2013-04-25
ES2631028T3 (es) 2017-08-25
CA2784624C (en) 2021-05-04
CN102770447B (zh) 2015-03-11
HK1177749A1 (en) 2013-08-30
US9273109B2 (en) 2016-03-01
KR20120108985A (ko) 2012-10-05
US20140356324A1 (en) 2014-12-04
US8415151B2 (en) 2013-04-09
SG181785A1 (en) 2012-07-30
WO2011072487A1 (zh) 2011-06-23
CA2784624A1 (en) 2011-06-23
EP2514761A4 (en) 2013-08-28
AU2010333574B2 (en) 2017-03-09
AU2010333574A1 (en) 2012-07-19
EP2514761B1 (en) 2016-11-23
EP2514761A9 (en) 2013-02-06
US20110158941A1 (en) 2011-06-30
EP2514761A1 (en) 2012-10-24
US8846025B2 (en) 2014-09-30
CN102770447A (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
CN102101886A (zh) 构象改变的重组干扰素晶体、其三维结构及应用
Emsley et al. Crystal structure of the I domain from integrin α2β1
US8114395B2 (en) Treatment of viral diseases with recombinant interferon α
EP1360200A2 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
US8287852B2 (en) Treatment of viral diseases with recombinant interferon α
US20150031859A1 (en) Use of new recombinant interferons with altered spatial configuration and three-dimensional structure
WO2002062375A1 (en) Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
US20150174206A1 (en) Uses of interferons with altered spatial structure
US9944686B2 (en) Treatment of tumors with recombinant interferon alpha
EP1663110A2 (en) Uses of interferons with altered spatial structure
WO2002062842A1 (en) Modified keratinocyte growth factor (kgf) with reduced immunogenicity
EP1392731A2 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
TWI513706B (zh) The spatial conformation changes the reconstructed interferon crystal, its three - dimensional structure and its application
US20060035327A1 (en) Recombinant super-compound interferon and uses thereof
CN104292330B (zh) 一种稳定性高的人源抗vegf抗体及其应用
HK1177749B (en) Crystalline recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
Shrestha et al. Peptides and Peptidomimetics
AU2002257579A1 (en) Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity
AU2002254910A1 (en) Modified ciliary neurotrophic factor (CNTF) with reduced immunogenicity
AU2002249180A1 (en) Modified keratinocyte growth factor (KGF) with reduced immunogenicity
AU2002229744A1 (en) Modified interleukin-1 receptor antagonist (IL-1RA) with reduced immunogenicity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110622